Epigenic joins Bayer Co.Lab in China
Shanghai, China, December 10, 2024 – Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, today announced that it has signed agreement with Bayer. Epigenic will join Bayer Co.Lab in China as a resident company, gaining access to Bayer’s global network and expertise to accelerate breakthrough innovations in epigenetic modulation technology.
“We are honored and excited to join Bayer Co.Lab, a leading innovation hub that aligns perfectly with our mission to revolutionize drug development through epigenetic modulation technology. This partnership provides us with an unique opportunity to collaborate with world’s leading pharmaceutical company to accelerate Epigenic’s groundbreaking technology and pipeline development by leveraging Bayer’s resources, expertise, and network. We look forward to bringing novel treatment solutions to patients with chronic diseases globally”, said Bob Zhang, CEO and Co-founder of Epigenic Therapeutics.
“We warmly welcome Epigenic to our vibrant Bayer Co.Lab community,” said Friedemann Janus, PhD, Senior Vice President and Global Head of Bayer Co.Lab, Regional Business Development & Licensing and Divestitures at Bayer Pharmaceuticals. “Our newly inaugurated site in China is quickly becoming a cornerstone for collaboration within the country's innovation ecosystem. Our global life science incubator network, Bayer Co.Lab, is committed to providing customized support that will nurture the growth and success of local biotech startups, especially as we observe an exciting wave of innovations in China.”
Bayer Co.Lab inaugurated its new site in China this September as part of its global network of life sciences incubators. Bayer Co.Lab not only provides resident companies the state-of-the-art infrastructure and lab space but will also access to Bayer's global R&D network and expertise and help biotech startups connect with global pharma industry resources. In China, Bayer Co.Lab aims to empower local biotech startups with a focus on cutting-edge innovations in the areas of CGT, oncology and new technology platforms. With the inauguration of its new site in Berlin this November, Bayer Co.Lab has been expanding its presence at global innovation hubs, including China, United States, Japan, and Germany, dedicated to supporting local startups to accelerating their innovations.
About Epigenic Therapeutics
Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene modulation therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene modulation technologies and developing gene modulation therapies, the company has multiple product candidates in the pipeline, including treatment for ocular, neurodegeneration, metabolic, and rare diseases. For more information, please visit www.epigenictx.com.
Contact
Investor@epigenictx.com
